Selected article for: "current approach and epidemic study"
Author: Jing-Wen Ai; Hao-Cheng Zhang; Teng Xu; Jing Wu; Mengqi Zhu; Yi-Qi Yu; Han-Yue Zhang; Zhongliang Shen; Yang Li; Xian Zhou; Guo-Qing Zang; Jie Xu; Wen-Jing Chen; Yong-Jun Li; De-Sheng Xie; Ming-Zhe Zhou; Jing-Ying Sun; Jia-Zhen Chen; Wen-Hong Zhang
Title: Optimizing diagnostic strategy for novel coronavirus pneumonia, a multi-center study in Eastern China
  • Document date: 2020_2_17
    • ID: nqxo3f45_30
    Snippet: Our study discovered that, in low epidemic regions outside Hubei province such as Eastern-China region, the current reliable first approach to the unexplained pneumonia should be a combination of chest CT, SARS-COV-2 RT-PCR and multi-plex PCR (rapid influenza antigen tests and RT-PCR could also be used as a substitute). Chest CT alone could not precisely diagnose COVID-2019 due to similar radiological presentations. Co-infection of other pathogen.....
    Document: Our study discovered that, in low epidemic regions outside Hubei province such as Eastern-China region, the current reliable first approach to the unexplained pneumonia should be a combination of chest CT, SARS-COV-2 RT-PCR and multi-plex PCR (rapid influenza antigen tests and RT-PCR could also be used as a substitute). Chest CT alone could not precisely diagnose COVID-2019 due to similar radiological presentations. Co-infection of other pathogens with SARS-COV-2 exists and should be acknowledged. What's more, different sampling approaches may also affect the results, therefore, in highly suspected cases but with two negative SARS-COV-2 RT-PCR results, repeated sampling or change of sample type could increase the positive rate. Metagenomics sequencing could further facilitate during critical clinical cases and monitor the molecular evolution for SARS-COV-2. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

    Search related documents:
    Co phrase search for related documents
    • antigen test and epidemic region: 1
    • antigen test and pathogen infection: 1
    • antigen test and positive rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • change sampling and Hubei province: 1
    • clinical case and critical clinical case: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • clinical case and Hubei province: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • clinical case and pathogen infection: 1, 2, 3
    • clinical case and positive rate: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • co pathogen infection and pathogen infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • critical clinical case and pathogen infection: 1
    • Eastern China region and epidemic region: 1, 2
    • Eastern China region and Hubei province: 1
    • epidemic region and Hubei province: 1, 2, 3, 4, 5, 6
    • epidemic region and positive rate: 1, 2, 3
    • epidemic region and positive rate increase: 1
    • Hubei province and molecular evolution: 1, 2, 3
    • Hubei province and pathogen infection: 1
    • Hubei province and positive rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • metagenomic sequence and molecular evolution: 1